Amgen Inc ((AMGN)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Amgen Inc. and AstraZeneca have announced a new clinical study titled A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease. The study aims to assess the effectiveness and safety of Tezepelumab, a promising treatment for adults with moderate to very severe COPD, a condition that significantly impacts quality of life and healthcare systems worldwide.
The intervention being tested is Tezepelumab, administered via subcutaneous injection every four weeks. This biological treatment is designed to reduce COPD exacerbations and improve patient outcomes.
The study is structured as a randomized, double-blind, placebo-controlled trial with a parallel group design. Participants are randomly assigned to receive one of two doses of Tezepelumab or a placebo, with the primary goal of evaluating treatment efficacy.
The study began on March 18, 2025, with primary completion expected in the coming months. The last update was submitted on July 22, 2025, indicating ongoing recruitment and progress.
This study could significantly impact Amgen and AstraZeneca’s market positions, potentially boosting investor confidence if results are favorable. The COPD treatment market is competitive, and successful outcomes could enhance these companies’ standings against rivals.
The study is currently ongoing, with further details available on the ClinicalTrials portal.